Avita Medical – Rights Issue Raises $12.4 Million

Avita Medical announces Rights Issue raises $12.4 million Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the results of the Non-Renounceable Rights Issue. The Board of Avita Medical Limited is pleased […]

Avita Medical and BARDA Execute a US$24.3m Contract Option

Valencia, CA, USA, Perth, Australia and London, United Kingdom, 21 September 2017 — Avita Medical (ASX: AVH), (OTCQX: AVMXY),  – link here a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes […]

Dr Michael S. Perry appointed Avita Medical CEO

US-based CEO aligns with Avita’s increasing US orientation with BARDA contract, completed Phase 3 trial, imminent PMA submission, and pending US approval & commercialization • Mike Perry former Novartis Executive – Prior SVP & Chief Scientific Officer of Business Development and previous Chief Scientific Officer of Novartis’ Cell & Gene Therapy Unit • Adam Kelliher […]

Avita Medical’s Board show confidence in company by taking payment in shares

Directors take up to 100 per cent of fees in shares • Follows shareholder approval of employee share plan in November last year Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom, 23 May 2017 —link here The board of pioneering regenerative medicine company Avita Medical Limited (ASX: AVH; OTCQX: AVMXY), have shown a strong […]

Avita Medical Announces Positive Results from Pivotal Trial

Highlights • Co-primary endpoints achieved in pivotal trial deploying ReCell® in patients with severe burns • Positive results also seen in another supportive trial • Company on-track to file a PMA with the U.S. Food & Drug Administration in mid-2017 • Avita primed to execute on U.S. commercialization strategy as early as Q2 2018 Valencia, […]

Avita Medical initiates legal proceedings to cancel Renovacare patent

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 11 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has filed an Inter Partes Review (IPR) petition against US Patent No. 9,610,430 (the ‘430 patent) owned by Renovacare Sciences Corp., as […]

Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 10 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has received notification of the initial FDA review of the Pre-EUA (Emergency Use Authorization) submission to allow the emergency deployment of its […]

U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries

U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries • Up to 48 patients can now be treated at 15 US burnscenters • Increased use of ReCell® device by US surgeons under the Compassionate Use dispensations • Latest FDA approval separate to approval earlier in the month for Continued […]

Quarterly Report and Update from CEO

CEO Shareholder Letter and Quarterly Report Dear Shareholder, link here As we conclude another quarter, it’s appropriate that I bring you, our owners, up-to-date on the progress Avita has made in recent months. US Approval Program Update The big goal that our team is working towards is entry to the US market, and I am […]

Avita Medical to Participate in the 3rd annual Biotech and Money / Medtech and Money London 2017 Conference

Northridge, CA, Perth, Australia and London, United Kingdom – 25 January 2017 – link here. Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that Adam Kelliher, Avita’s Chief Executive Officer, will be a panel member at the Biotech and Money / […]